2. Academic Validation
  3. Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization

Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization

  • Adv Drug Deliv Rev. 2016 Feb 1:97:56-68. doi: 10.1016/j.addr.2015.12.016.
Andrew J Sawyer 1,  Themis R Kyriakides 2
Affiliations

Affiliations

  • 1 Department of Pathology, Yale School of Medicine, 310 Cedar Street LH 108, New Haven, CT 06520-8023, USA.
  • 2 Department of Pathology, Yale School of Medicine, 310 Cedar Street LH 108, New Haven, CT 06520-8023, USA; Department of Biomedical Engineering, Yale University, New Haven, CT, USA; Vascular Biology and Therapeutics Program, Yale University, New Haven, CT, USA. Electronic address: themis.kyriakides@yale.edu.
PMID: 26763408 DOI: 10.1016/j.addr.2015.12.016
Abstract

Extracellular matrix is composed of a complex array of molecules that together provide structural and functional support to cells. These properties are mainly mediated by the activity of collagenous and elastic fibers, proteoglycans, and proteins such as fibronectin and laminin. ECM composition is tissue-specific and could include matricellular proteins whose primary role is to modulate cell-matrix interactions. In adults, matricellular proteins are primarily expressed during injury, inflammation and disease. Particularly, they are closely associated with the progression and prognosis of cardiovascular and fibrotic diseases, and Cancer. This review aims to provide an overview of the potential use of matricellular proteins in drug delivery including the generation of therapeutic agents based on the properties and structures of these proteins as well as their utility as biomarkers for specific diseases.

Keywords

Angiogenesis; Cell–matrix interactions; Extracellular matrix; Fibrosis; Matricellular.

Figures
Products